AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02337829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib (Arm A)
Description: * A1a) acalabrutinib, dose A daily: biopsy (T) schedule W;~* A1b) acalabrutinib, dose A daily: biopsy (T) schedule V.~* A2a) acalabrutinib, dose B q 12 hours: biopsy (T) schedule Y;~* A2b) acalabrutinib, dose B q 12 hours; biopsy (T) schedule Z
Study NCT02337829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib (Arm B)
Description: B1c) acalabrutinib, dose A daily: biopsy (U) schedule W;~• B2c) acalabrutinib, dose B q12 hours: biopsy (U)) schedule Y.
Study NCT04064060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Luspatercept (ACE-536), an erythroid maturation agent, is a recombinant fusion protein consisting of a modified form of the extracellular domain (ECD) of the human activin receptor type IIB (ActRIIB) linked to the human immunoglobin G 1 (IgG1) Fc domain. ActRIIB receptor and its ligands are members of the transforming growth factor-β (TGF-β) superfamily. Members of the TGF-β superfamily ligands, through their binding to activin receptors, are involved in modulating the differentiation of late-stage erythrocyte precursors (normoblasts) in the bone marrow. Luspatercept for injection is formulated as a sterile, preservative-free, lyophilized cake/powder. Luspatercept for injection is available in 25 mg and 75 mg vials and when reconstituted with water for injection, each consists of 50 mg/mL luspatercept in a 10 mM citrate buffer-based solution
Study NCT02143726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sorafenib
Description: Given PO
Study NCT06778161 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: nerve block
Description: Nerve block for providing analgesia after thoracotomy
Study NCT01352221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matching placebo capsules for ST10 to be taken orally twice a day for 12 weeks in double-blind phase
Study NCT03219034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oral appliance - A ; washout; oral appliance B
Description: Anti-snoring intra-oral appliance A that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible. 1 week washout followed by anti-snoring intra-oral appliance B that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs.
Study NCT03219034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oral appliance - B; washout; oral appliance A
Description: Anti-snoring intra-oral appliance B that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs. 1-week washout followed by anti-snoring intra-oral appliance A that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible.
Study NCT02143726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: Given PO
Study NCT02143726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO
Study NCT03092674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Given SC or IV
Study NCT03092674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV
Study NCT03092674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT03092674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT03092674 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03092674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03092674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Given PO
Study NCT03092674 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03774082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC424
Description: Ruxolitinib is taken orally either as 5mg tablets or as pediatric formulation (dosage based on age group)
Study NCT03707899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-1401
Description: Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
Study NCT01691105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AD + Integrated Tobacco Order Set
Description: Physician will have access to:~NRT with dosing instructions Bupropion and varenicline with dosing instructions Automated referral to the CT Quitline Automated fax to PCP Discharge prescription prompt Quitline report sent to PCP 2 day call back from hospital call center
Study NCT01597908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib 150 mg twice daily orally
Study NCT01597908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vemurafenib
Description: Vemurafenib 960 mg twice daily orally
Study NCT01597908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib 2 mg once daily orally
Study NCT03007329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Exenatide will be combined with Dapagliflozin
Study NCT03007329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exenatide matching Placebo
Description: Exenatide matching Placebo will be combined with Dapagliflozin
Study NCT03007329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin, in both arms
Study NCT03007329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin, in both arms
Study NCT02674919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic Hamstring
Study NCT02674919 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Study NCT01186926 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HGNS Treatment
Description: The Apnex Hypoglossal Nerve Stimulation (HGNS) System is an implanted medical device that is designed to prevent the tongue from blocking the airway during sleep. It is fully automatic and can be implanted during a simple surgical procedure. After it is implanted, the device is programmed to meet the unique needs of each patient. The device is on when the patient is sleeping, and off when the patient is awake.
Study NCT01287390 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: video fluoroscopy
Description: video fluoroscopy of swallowing function at baseline, 6 months and 12 months follow-up
Study NCT03707899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JLP-1401
Description: Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
Study NCT03707899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine, Rosuvastatin
Description: Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
Study NCT03707899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan/Amlodipine, Rosuvastatin
Description: Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
Study NCT03317652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperventilation
Description: The subject is instructed to hyperventilate for 6 min to provoke a 0.7-1.2 kPa reduction in PaCO2, and the evaluation is repeated if the reduction in PaCO2 is not within this interval. The order of hyperventilation and 6% CO2 breathing is randomized.
Study NCT03317652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6% CO2 breathing
Description: The subject breathes a mixture of 6% CO2 (with 21% O2 and 73% N2) from a bag and a face mask for 6 minutes. The order of hyperventilation and 6% CO2 breathing is randomized.
Study NCT03317652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusion of sodium nitroprusside
Description: Using incremental intravenous infusion of sodium nitroprusside MAP is reduced by 20% (15%-25%) and then by 40% (35%-45%, MAP minimally at 50 mmHg).
Study NCT04532164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butenafine HCl 1% (BAY1896425) - Induction Phase
Description: To each of two test sites, approximately 20 μl/cm\^2 of the Butenafine HCl 1% was applied directly to the skin and covered with a 25 mm Hilltop chamber with a Webril pad (2 cm in diameter, within an area of approximately 3 cm\^2), and tape was applied over the chamber to secure the occlusive patch to the skin. On the next day, the chambers were removed and both test sites were lightly wiped. Approximately 2 μl/cm\^2 of Butenafine HCl 1% was reapplied directly to the skin and lightly spread over the treated irradiated test site. The treated non-irradiated test site did not receive a similar reapplication. Between 5 and 15 minutes after application, the treated irradiated test site was irradiated with two times the subject's Minimal Erythema Dose (MED). Evaluation of the test sites occurred two days after the irradiation. This procedure was repeated two times per week for three consecutive weeks for a total of 6 induction exposures per test site.
Study NCT04532164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butenafine HCl 1% (BAY1896425) - Challenge Phase
Description: 5 μl/cm\^2 of the Butenafine HCl 1% was applied directly to each of the two virgin sites (treated sites) adjacent to the induction patch sites and covered with Hilltop chambers with Webril pad and tape was applied over the chambers to secure the occlusive patches to the skin. Two additional sites with no Butenafine HCl 1% (untreated sites) were also occluded. Sites were at least 2.5 cm apart. The patches were removed 24 hours later and the sites were lightly wiped. Test sites were evaluated. Butenafine HCl 1% (2 μl/cm\^2) was applied to the treated irradiated site. After 15 minutes, the treated irradiated site and the untreated irradiated site were irradiated with 0.5 MED of UVA/UVB irradiation followed by 10 Joules/cm\^2 of UVA from a xenon arc solar simulator equipped with a Schott WG345 to eliminate UVB radiation. The remaining sites served as the treated non-irradiated site and untreated non-irradiated site.
Study NCT03590899 — intervention group
Intervention type: DEVICE
Intervention: Optical coherence tomography angiography (Zeiss Cirrus HD OCT 5000 AngioPlex)
Description: Non-invasive, non-contact optical coherence tomography angiography scans of the retina are done per built-in device protocol using the Zeiss Cirrus HD OCT 5000 AngioPlex machine.
Study NCT00775866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI-Guided Biopsy
Description: Technical development and clinical testing of a novel technique for magnetic resonance imaging (MRI) guided prostate biopsy in a 1.5T horizontal bore scanner using a dedicated interventional table.
Study NCT02071134 — intervention group
Intervention type: DEVICE
Intervention: Deep Brain Stimulation (DBS)
Description: Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their Parkinson's disease symptoms will be offered participation in this registry.
Study NCT00600353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Palonosetron 0.25 mg IV over 30 seconds
Study NCT00600353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant 125 mg PO and Aprepitant 80 mg PO
Study NCT00600353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 4 mg IV and Dexamethasone 4 mg IV push
Study NCT02457936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: 8 weekly meetings in which basic mindfulness and meditation skills are taught, such as breathing meditation, body scan meditation, open awareness meditation, movement meditation, and targeting depression related cognitions and emotions in a mindful manner, as well as awareness exercises, group discussions, and daily home meditation practice routines
Study NCT00720434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00868554
Description: 500 mg BID administered as 5x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks.
Study NCT00720434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00868554
Description: 300 mg BID administered as 3x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
Study NCT00720434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00868554
Description: 200 mg BID administered as 2x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
Study NCT00720434 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
Study NCT02487693 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation is performed percutaneously under CT/US guidance
Study NCT02487693 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced killer cells
Description: The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
Study NCT02464462 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3 and calcium
Description: 1800 IU vitamin D3 plus 720 mg Calcium
Study NCT02464462 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rice powder pills
Study NCT00189254 — intervention group
Intervention type: DRUG
Intervention: Imiquimod
Description: No defined treatments were given during this study.
Study NCT04459091 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Essential Acid
Description: 8 gr die in two administration
Study NCT04459091 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 8 gr die in two administration
Study NCT02399501 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hysteroscopy
Description: Hysteroscopy is done under general anesthesia. The hysteroscopy used is rigid continuous flow diagnostic hysteroscopy (Tuttligen, Karl Storz, Germany). It has a 30º panoramic optic which is 4 mm in diameter and the diagnostic continuous flow outer sheath is 6.5 mm in diameter.
Study NCT02399501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: two dimensional ultrasound
Description: Examination is performed after emptying of the bladder in dorsal lithotomy position .The probe is introduced into the posterior fornix of the vagina, then the following structures are examined, the uterus for site, size and mobility, the myometrium for fibroids and adenomyosis, the endometrium for uniformity, polyps, submucous fibroids and intrauterine adhesions, the cervix for nabothian follicles and polyps, the adenexa and ovaries for site, size, mobility, follicles, cysts and corpus luteum
Study NCT02399501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: saline sonohysterography
Description: sterile speculum is introduced and the vagina and cervix is cleaned with povidone iodine 10%. Cook ET (embryo transfer) catheter is used. . After introduction of the catheter into the cervix, a twenty milliliter syringe which will be prefilled with the distending media (saline) then fitted to the catheter. The speculum is removed and endovaginal probe is introduced in the posterior vaginal fornix
Study NCT02399501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: three dimensional ultrasound
Description: The uterus is visualized in the longitudinal plane, the ultrasound probe is kept steady and the patient is asked to lie still on the examination bed. The volume mode is switched on. Three D volume is generated by the automatic rotation of the mechanical transducer through 360º. The acquired volume is in the shape of a transacted cone with a depth of 4.3 - 8.6 cm and a vertical angle α = 90º. Using the medium line density, the typical acquisition time is a round 10 seconds
Study NCT02457936 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Cognitive Therapy
Description: 8 weekly meetings in which basic mindfulness and meditation skills are taught, such as breathing meditation, body scan meditation, open awareness meditation, movement meditation, and targeting depression related cognitions and emotions in a mindful manner, as well as awareness exercises, group discussions, and daily home meditation practice routines
Study NCT05634304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A mobile app self-management (mSM) program
Description: The mSM program is developed on Bundura's self-efficacy theory, which provides four sources of information for SM. The strategies of the mSM consist of mobile app to management program including peer support, appraisal, goal setting and self-monitoring of exercise for OA and symptom management.
Study NCT01633333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water exchange colonoscopy
Description: Water is infused and suctioned in a systematic fashion to obtain luminal view and for cleansing of the colon to facilitate colonoscope insertion. The carbon dioxide pump is turned off, only to be turned on during withdrawal from the cecum.
Study NCT01633333 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbon dioxide insufflation
Description: Carbon dioxide insufflation to obtain luminal view to facilitate colonoscope insertion, considered to be standard procedure.
Study NCT04039815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic acid-Vitamin B1-Hydrocortisone
Description: intravenous Thiamine (200mg in 50 mL of 0.9% normal saline and was administered as a 30-min infusion every 12 hours for 4 days or until ICU discharge), plus Vitamin C (1.5g mixed in a 100-mL solution of normal saline and was administered as an infusion over 30 to 60 min every 6 hours for four days or until ICU discharge) as well as hydrocortisone 50mg every 6 hours (or other equivalent products) for 7 days
Study NCT04039815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients would receive 50mL 0.9% normal saline, 100 mL 0.9% normal saline with the same infusion rate and hydrocortisone dependent on the discretion of the attending physician
Study NCT02669381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Phenylalanine intake
Description: Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
Study NCT01896544 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 7ml syringe of cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube
Study NCT01896544 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7ml syringe of placebo cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube
Study NCT03152851 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pressure stimulus group
Study NCT05809401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pragmatic Rehabilitation
Description: A series of behavioral activities to improve specific pragmatic abilities in patients
Study NCT05809401 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological Rehabilitation
Description: A series of behavioral activities to improve general aspect of cognition, with a specific focus on attentional abilities.
Study NCT04373135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief educational video
Description: A brief educational video will be displayed explaining the mechanics of how SRA policies operate, how they are decided, and what patients' and healthcare workers' rights are surrounding them.
Study NCT00007150 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Phlebotomy
Description: Therapeutic phlebotomy, the periodic, frequent removal of the iron contained in the hemoglobin of red blood cells.
Study NCT05238714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venglustat
Description: Powder for Oral solution
Study NCT01120704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short Term Combination Nicotine Replacement Therapy (patch + gum)
Description: IF participant smokes >10 cigs/day AND is randomized to a 8 week condition: they will be asked to take one 21 mg patch/day for 4 weeks, THEN one 14 mg patch/day for 2 weeks, THEN one patch 7mg/day for 2 weeks.Participants will also be asked to use 4-mg gum every 1-2 hours (9 pieces maximum per day)for 6 weeks and decrease gum use over the 2 weeks prior to medication termination until down to one gum piece every 4-8 hours by the last week of treatment.~IF participant smokes 5-10 cigs/day AND is randomized to the 8 week medication condition: they will be asked to take one 14 mg patch/day for 4 weeks, THEN one 7 mg patch/day for 4 weeks. Participants will also be asked to use 2-mg gum every 1-2 hours (9 pieces max per day)for 6 weeks and decrease gum use over the 2 weeks prior to medication termination until down to one gum piece every 4-8 hours by the last week of treatment.